- Home
- USGO vs LUNG Comparison
USGO vs LUNG Comparison
Compare USGO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- LUNG
- Stock Information
- Founded
- USGO 2015
- LUNG 1995
- Country
- USGO United States
- LUNG United States
- Employees
- USGO N/A
- LUNG N/A
- Industry
- USGO Precious Metals
- LUNG Industrial Specialties
- Sector
- USGO Basic Materials
- LUNG Health Care
- Exchange
- USGO Nasdaq
- LUNG Nasdaq
- Market Cap
- USGO 117.3M
- LUNG 106.3M
- IPO Year
- USGO 2023
- LUNG 2020
- Fundamental
- Price
- USGO $8.37
- LUNG $3.11
- Analyst Decision
- USGO Strong Buy
- LUNG Buy
- Analyst Count
- USGO 1
- LUNG 6
- Target Price
- USGO $26.50
- LUNG $11.53
- AVG Volume (30 Days)
- USGO 31.1K
- LUNG 401.8K
- Earning Date
- USGO 08-12-2025
- LUNG 07-30-2025
- Dividend Yield
- USGO N/A
- LUNG N/A
- EPS Growth
- USGO N/A
- LUNG N/A
- EPS
- USGO N/A
- LUNG N/A
- Revenue
- USGO N/A
- LUNG $87,473,000.00
- Revenue This Year
- USGO N/A
- LUNG $18.02
- Revenue Next Year
- USGO N/A
- LUNG $18.17
- P/E Ratio
- USGO N/A
- LUNG N/A
- Revenue Growth
- USGO N/A
- LUNG 19.84
- 52 Week Low
- USGO $5.00
- LUNG $2.50
- 52 Week High
- USGO $14.46
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- USGO 43.70
- LUNG 51.48
- Support Level
- USGO $8.18
- LUNG $3.03
- Resistance Level
- USGO $9.11
- LUNG $3.88
- Average True Range (ATR)
- USGO 0.40
- LUNG 0.33
- MACD
- USGO 0.02
- LUNG 0.05
- Stochastic Oscillator
- USGO 53.37
- LUNG 41.54
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.